Bruce Pyenson

Summary

Affiliation: Milliman USA
Country: USA

Publications

  1. pmc A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions
    Andrea C Villanti
    The Schroeder Institute for Tobacco Research and Policy Studies, Legacy, Washington, DC, United States of America
    PLoS ONE 8:e71379. 2013
  2. pmc Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and Medicare populations
    Bruce Pyenson
    Milliman, Inc, One Pennsylvania Plaza, 38th Floor, New York, NY 10119, USA
    BMC Health Serv Res 14:92. 2014
  3. doi A Medicaid and commercial insured claims-based study to estimate improved antipsychotic medication adherence among patients with schizophrenia
    Bruce Pyenson
    Milliman, Inc, One Pennsylvania Plaza, 38th Floor, New York, NY 10119, USA
    J Behav Health Serv Res 40:222-33. 2013
  4. doi An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost
    Bruce S Pyenson
    Milliman, New York City, New York, USA
    Health Aff (Millwood) 31:770-9. 2012
  5. pmc MAKING THE CASE FOR Biotechnology Reinsurance (BIO-RE)
    Bruce Pyenson
    is a principal and a consulting actuary at Milliman Inc, in New York He can be reached by e mail at or by phone at 646 473 3201
    Biotechnol Healthc 5:31-5. 2008
  6. doi Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis
    Kathryn Fitch
    Milliman, Inc, New York, NY, USA
    Curr Med Res Opin 27:1425-9. 2011

Detail Information

Publications6

  1. pmc A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions
    Andrea C Villanti
    The Schroeder Institute for Tobacco Research and Policy Studies, Legacy, Washington, DC, United States of America
    PLoS ONE 8:e71379. 2013
    ....
  2. pmc Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and Medicare populations
    Bruce Pyenson
    Milliman, Inc, One Pennsylvania Plaza, 38th Floor, New York, NY 10119, USA
    BMC Health Serv Res 14:92. 2014
    ..The incidence and mortality associated with CRC can be reduced with preventive screening. Inadequate bowel preparation has been associated with missed adenomas and the need for repeat colonoscopies...
  3. doi A Medicaid and commercial insured claims-based study to estimate improved antipsychotic medication adherence among patients with schizophrenia
    Bruce Pyenson
    Milliman, Inc, One Pennsylvania Plaza, 38th Floor, New York, NY 10119, USA
    J Behav Health Serv Res 40:222-33. 2013
    ..For many of these patients, results show that the administration of once-monthly verifiable therapy would improve compliance...
  4. doi An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost
    Bruce S Pyenson
    Milliman, New York City, New York, USA
    Health Aff (Millwood) 31:770-9. 2012
    ..We also believe that payers and patients should demand screening from high-quality, low-cost providers, thus helping set an example of efficient system innovation...
  5. pmc MAKING THE CASE FOR Biotechnology Reinsurance (BIO-RE)
    Bruce Pyenson
    is a principal and a consulting actuary at Milliman Inc, in New York He can be reached by e mail at or by phone at 646 473 3201
    Biotechnol Healthc 5:31-5. 2008
    ..The author proposes a combined cost-management and care-delivery standard that could lessen that threat...
  6. doi Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis
    Kathryn Fitch
    Milliman, Inc, New York, NY, USA
    Curr Med Res Opin 27:1425-9. 2011
    ..In this claims based analysis of COPD patients, drug therapy treatment patterns including inhaled corticosteroids and long acting bronchodilator use were evaluated by COPD severity level...